Progress on molecular markers of pancreatic cancer

Grote, Tobias; Logsdon, Craig D.

doi:10.1097/mog.0b013e3282ba5724

Cited by 51 publications

(36 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other biomarkers such as duke pancreatic monoclonal antigen type 2 (DUPAN-2), macrophage inhibitory cytokine (MIC-1), regenerating islet derived (REG-4) which are unaffected by Lewis blood group status may be more effective for this population. [7,[80][81][82] Additional strategies include simultaneous measurement of disialyl Lewis a (normal counterpart) during CA 19-9 evaluation. The ratio of sLea (CA 19-9)/disialyl Lewis may provide an improved serum diagnosis by averting undesired effect of a Lewis-blood group negative phenotype and reducing the false-positive rate (non-specific elevation) [7].…”

Section: Limitations Of Ca 19-9 Serum Levels As a Pancreatic Cancer Bmentioning

confidence: 99%

Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review

Ballehaninna

Chamberlain

2011

Indian J Surg Oncol

213

161

View full text Add to dashboard Cite

show abstract

Section: Limitations Of Ca 19-9 Serum Levels As a Pancreatic Cancer Bmentioning

confidence: 99%

Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review

Ballehaninna

Chamberlain

2011

Indian J Surg Oncol

213

161

View full text Add to dashboard Cite

show abstract

“…Many studies have reported that pancreatic juice is a rich source of proteins released directly from PC cells, and is an available and useful specimen to identify PC-related antigens (5,8,9). To produce monoclonal antibodies specific for pancreatic juice from PC patients, we immunized mice using subtractive immunization.…”

Section: Discussionmentioning

confidence: 99%

“…Many studies have reported that pancreatic juice is a useful specimen to identify PC-related antigens, because it is secreted from the pancreatic ductal lumen from where PC cells arise (5,8,9). Particular antigens in pancreatic juice with specific and/or high expression in PC may be useful to differentiate between benign and malignant disease.…”

Section: Introductionmentioning

confidence: 99%

Novel monoclonal antibodies against pancreatic juice from pancreatic cancer patients and their possible application in differential diagnosis

Hamabashiri

Daichou²,

Yasumoto³

et al. 2011

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Pancreatic cancer (PC) has a poor clinical prognosis with a <10% 5-year survival rate. Because there are no specific biomarkers of PC, it is difficult to detect small PC tumors and most patients are diagnosed at an advanced stage. Specific biomarkers are useful tools for the early detection of cancer. However, PC-related biomarkers, such as CA19-9 lack specificity and sensitivity. In this study, we took an immunological approach to establish novel monoclonal antibodies (mAbs) specific for the pancreatic juice from PC patients, which would be potentially useful in the diagnosis of PC. Mice were immunized by subtractive immunization using mixed pancreatic juices from chronic pancreatitis and PC patients as the tolerogen and the immunogen, respectively. After screening by Western blotting, four mAbs were obtained: 2P-1-2-1, 2P-1-17-1, 6P-3-2-4 and 7P-9-11-6. The mAb 2P-1-2-1 showed reactivity against the tolerogen at 115 and 120 kDa, but only the 120-kDa antigen was also reactive to the immunogen. The mAb 2P-1-17-1 showed an intense smear reactivity at ~150 kDa against the immunogen. Finally, the mAbs 6P-3-2-4 and 7P-9-11-6 showed PC-specific reactivity to the immunogen at >250 kDa and at ~70 kDa, respectively. We propose that investigation of pancreatic juice samples with these mAbs may enable us to perform reliable differential diagnosis of benign and malignant diseases. Furthermore, we demonstrated that subtractive immunization is a useful method for producing mAbs specific for the pancreatic juice from PC patients.

show abstract

“…Blood markers like CA19-9 are not recommended as prognostic makers in PC [13][14][15][16]. The pathological staging has also recently been questioned since the definition of tumor-free resection margins is strongly dependent upon the type of histological work-up of the operative specimens [17][18][19].…”

Section: Introductionmentioning

confidence: 99%